JUXTAPID

This brand name is authorized in Canada, Japan, United States

Active ingredients

The drug JUXTAPID contains one active pharmaceutical ingredient (API):

1 Lomitapide
UNII X4S83CP54E - LOMITAPIDE MESYLATE

Lomitapide is a selective inhibitor of microsomal transfer protein (MTP), an intracellular lipid-transfer protein that is found in the lumen of the endoplasmic reticulum and is responsible for binding and shuttling individual lipid molecules between membranes. MTP plays a key role in the assembly of apo B containing lipoproteins in the liver and intestines. Inhibition of MTP reduces lipoprotein secretion and circulating concentrations of lipoprotein-borne lipids including cholesterol and triglycerides.

Read about Lomitapide

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
JUXTAPID Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C10AX12 C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AX Other lipid modifying agents
Discover more medicines within C10AX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02420341, 02420376, 02420384
Country: JP 医薬品医療機器総合機構 Identifier(s): 2189020M1023, 2189020M2020, 2189020M3026
Country: US FDA, National Drug Code Identifier(s): 76431-105, 76431-110, 76431-120, 76431-130

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.